Israeli Drugmaker Teva Reports Strong Revenue Growth as Branded Sales Top $1B...

Teva Pharmaceutical Industries reported strong revenue growth in its latest quarter, with branded drugs surpassing $1 billion in sales. The company beat analyst expectations and raised its outlook despite posting a net loss tied to the Emalex acquisition.

The results highlight continued momentum in Teva's core operations amid integration costs from recent deals.